NCI-H1792 cell

NCI-H1792 is a human non-small cell lung carcinoma (NSCLC) cell line derived from a lung adenocarcinoma of an adult patient. It has been utilized extensively in cancer research, particularly in studies focusing on lung tumorigenesis, genetic aberrations, and drug sensitivity profiling. The cell line is characterized by an epithelial morphology and forms adherent monolayers in culture. Its inclusion in large-scale datasets such as the Cancer Cell Line Encyclopedia (CCLE) has enabled extensive genomic and proteomic profiling, facilitating comparative analyses with other lung cancer models. Genomically, NCI-H1792 exhibits several molecular alterations common in NSCLC. It is known to harbor a KRAS mutation, a common oncogenic driver in lung adenocarcinoma, which contributes to aberrant MAPK signaling. The cell line has also been analyzed in proteomic studies, where its protein expression profile has provided insight into signaling pathway dependencies and vulnerabilities. Proteomic data highlight its utility in understanding pathway regulation and drug target validation across KRAS-mutant cancers. These datasets also underscore its classification within a subtype of KRAS-driven cancers that show distinct metabolic and signaling characteristics. NCI-H1792 is typically cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum and maintained under standard cell culture conditions (37°C, 5% CO₂). Its moderate growth rate and epithelial phenotype make it suitable for high-throughput drug screening and pathway interrogation studies. Due to its defined mutational background and widespread profiling, NCI-H1792 serves as a reliable model for exploring therapeutic responses in KRAS-driven lung adenocarcinomas.

SKU:BHC11101698

• SDS (0193773BC5D17ACA89BDEF95F5399DB1)
• Product Sheet (0193773BC5D17ACA89BDEF95F5399DB1)
• NCI-H1792 305835-101025 Cytion CoA (PDF)

Mutational profile: Mutation: CDKN2A, Simple, p.Trp110Ter (c.330G>A) (p.Gly125Arg, c.373G>A), Heterozygous.Mutation, KRAS, Simple, p.Gly12Cys (c.34G>T), Heterozygous, TP53, Simple, c.672+1G>A, Homozygous, Note=Splice donor mutation

• cultureMedium: RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a)
• supplements: Supplement the medium with 10% FBS
• dissociationReagent: Accutase
• doublingTime: 45 hours
• fluidRenewal: 2 to 3 times per week
• freezeMedium: As a cryopreservation medium, use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress.